黄芪续命汤联合西药治疗对阿尔茨海默病患者认知功能及生活质量的影响#
DOI:
作者:
作者单位:

1.江苏省宿迁市泗阳康达医院神经内科;2.宿迁市中医院脑病科

作者简介:

通讯作者:

中图分类号:

基金项目:


Effects of Huangqi Xunming Decoction combined with Western medicine on cognitive function and quality of life in Alzheimer"s disease patients#
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的:研究探讨阿尔茨海默病患者接受黄芪续命汤+西药治疗,对于其认知功能、生活质量的影响。方法:研究于2021年1月1日—2023年12月31日,收集本院阿尔茨海默病病例70例,将其作为研究对象进行分组比较。对照组采取常规西药(盐酸多奈哌齐片)治疗,观察组在西药治疗基础上,联合中药黄芪续命汤,比较两组生活质量、认知功能等指标。结果:治疗前,两组患者的阿尔茨海默病认知功能评定表(Alzheimer"s disease assessment scale-cognitive subscale,ADAS-cog)评分比较差异无统计学意义(P>0.05);治疗后,观察组评分较对照组更低(P<0.05)。治疗后,两组患者日常生活能力量表(Activity of daily living scale,ADL)评分下降,观察组更低(P<0.05)。两组患者精神行为症状比较中,治疗后对照组的阿尔茨海默病行为病理学(Behavioral pathology in alzheimer"s disease rating scale,BEHAVE-AD)评分更高(P<0.05)。观察组与对照组的不良反应发生率分别为20.00%、17.14%,差异无统计学意义(P>0.05)。经治疗,观察组的β淀粉样蛋白1-42和苏氨酸181位点磷酸化Tau蛋白(Phosphorylated tau protein at threonine 181 residue,P-TAU-181)蛋白水平低于对照组(P<0.05)。对照组临床治疗有效率低于观察组(P<0.05)。结论:在中西医结合治疗下,阿尔茨海默病患者应用黄芪续命汤联合盐酸多奈哌齐片,对于提高生活质量有积极的影响,能够改善患者精神行为症状,延缓疾病进展,提高临床治疗效果,同时不会增加药物不良反应,具有安全性保障。

    Abstract:

    Objective: To study the effects of astragalus life-saving soup + western medicine on cognitive function and quality of life in patients with Alzheimer"s disease. Methods: From January 1, 2021 to December 31,2023, this study enrolled 70 Alzheimer"s disease patients at our hospital for comparative group analysis. The control group received conventional Western medication (donepezil hydrochloride tablets), while the observation group received a combination of Western medicine and traditional Chinese herbal formula Huangqi Xumian Decoction. The comparison focused on evaluating quality of life and cognitive function metrics between the two groups. Results: Prior to treatment, there was no statistically significant difference in the Alzheimer"s Disease Assessment Scale-Cognitive Subscale (ADAS-cog) scores between the two groups (P>0.05). After treatment, the observation group scored lower than the control group (P<0.05). Both groups showed decreased scores on the Activities of Daily Living Scale (ADL), with the observation group scoring even lower (P<0.05). In terms of psychiatric and behavioral symptoms, the control group exhibited higher behavioral pathological scores on the Behavioral Pathology in Alzheimer"s Disease Rating Scale (BEHAVE-AD) after treatment (P<0.05). The incidence rates of adverse reactions were 20.00% in the observation group and 17.14% in the control group, showing no statistically significant difference (P>0.05). Treatment resulted in lower levels of β-amyloid 1-42 and phosphorylated tau protein at threonine 181 (P-TAU-181) in the observation group compared to the control group (P<0.05). The clinical response rate was also lower in the control group than in the observation group (P<0.05). Conclusion: Under the combined treatment of Chinese and Western medicine, the application of Astragalus Xunming Decoction combined with Donepezil Hydrochloride Tablets in Alzheimer"s disease patients has a positive impact on improving the quality of life, can improve the mental and behavioral symptoms of patients, delay the progression of the disease, improve the clinical treatment effect, and at the same time, it does not increase the adverse drug reactions, and has a safe guarantee.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2025-07-28
  • 最后修改日期:2025-08-19
  • 录用日期:2025-08-28
  • 在线发布日期:
  • 出版日期: